Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Coffee grounds probiotic could reshape gut health and fight inflammation

NCT ID NCT06912100

Disease control Sponsor: University of Connecticut Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This pilot study tests whether a daily probiotic supplement containing L. acidophilus (strain TW01), originally isolated from fermented coffee grounds, can improve gut health, body composition, and markers of inflammation. Overweight or obese adults aged 18-60 will take either the probiotic or a placebo for a period, while researchers measure stool butyrate (a gut health marker), blood inflammation levels, and body fat percentage. The goal is to see if this probiotic can positively influence overall health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Probiotic L. acidophilus (strain TW01) plus a fiber source (Fibersol-2), taken as capsules daily
What this could lead to
If it works, this probiotic could support gut health, reduce inflammation, and improve body composition in people who are overweight or obese.
What could go wrong
This is a very small early-stage pilot study, so results may not apply broadly. The probiotic may have no significant effect, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-60 years 2. Body mass index (BMI) between 28 kg/m2 and 40 kg/m2 3. Waist circumference ≥ 88 cm or 35 inches for women, ≥ 102 cm or 40 inches for men 4. Willing to consume experimental capsules daily 5. Willing to prepare and consume the delivered meal kits 6. Do not fit any exclusion criteria Exclusion Criteria: 1. Self-reported history of immunodeficiency, major gastrointestinal surgery, renal or liver disease, diabetes, heart disease, stroke, peripheral artery/vascular disease, cancer, eating disorders, gut-associated pathologies, autoimmune diseases, pacemaker, thyroid disease, gallbladder disease, chronic inflammatory diseases, scleroderma, blood clotting disorders, intravenous drug use 2. Weight changes \> 10% over the last 4 weeks 3. Oral antibiotics and/or probiotics use up to 1 month prior to study and during study 4. Currently taking GLP-1 analogues (e.g., Ozempic), anti-inflammatory medications (e.g., corticosteroids), daily use of nonsteroidal anti-inflammatory drugs (NSAIDs) (occasional use is permitted), medications which primarily affect blood clotting (e.g., warfarin), or any medications that suppress the immune system. 5. Dairy allergy 6. Currently pregnant or breast-feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obese, otherwise healthy volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obese, otherwise healthy volunteers Overweight (bmi > 25)

Contacts and locations

Locations

  • University of Connecticut, Department of Nutritional Sciences

    Storrs, Connecticut, 06269, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.